A single dose of S-ketamine induces long-term antidepressant effects and decreases oxidative stress in adulthood rats following maternal deprivation

Developmental Neurobiology

Volumn 75, Issue 11, 2015, Pages 1268-1281

  Réus, Gislaine Z ^a,b   Carlessi, Anelise S ^a   Titus, Stephanie E ^b   Abelaira, Helena M ^a   Ignácio, Zuleide M ^a   da Luz, Jaine R ^a   Matias, Beatriz I ^a   Bruchchen, Livia ^a   Florentino, Drielly ^c   Vieira, Andriele ^c   Petronilho, Fabricia ^b,c   Quevedo, João ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Antioxidant enzymes; Depression; Ketamine; Maternal deprivation; Oxidative damage

Indexed keywords

CATALASE; ESKETAMINE; SUPEROXIDE DISMUTASE; ANTIDEPRESSANT AGENT; KETAMINE;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MATERNAL DEPRIVATION; MOOD; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANHEDONIA; ANIMAL; BRAIN; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CATALASE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; KETAMINE; LIPID PEROXIDATION; MALE; MATERNAL DEPRIVATION; OXIDATIVE STRESS; RATS, WISTAR; STRESS, PSYCHOLOGICAL; SUPEROXIDE DISMUTASE;

EID: 84943586062     PISSN: 19328451     EISSN: 1932846X     Source Type: Journal    
DOI: 10.1002/dneu.22283     Document Type: Article

References (96)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. 2012. Ketamine for depression: Where do we go from here? Biol Psychiatry 72:537-547.
2. Abdul-Muneer PM, Chandra N, Haorah J. Interactions of oxidative stress and neurovascular inflammation in the pathogenesis of traumatic brain injury. Mol Neurobiol, in press.
3. Abelaira HM, Réus GZ, Quevedo J. 2013. Animal models as tools to study the pathophysiology of depression. Rev Bras Psiquiatr 2:S112-S120.
4. Abelaira HM, Réus GZ, Ribeiro KF, Zappellini G, Cipriano AL, Scaini G, Streck EL, et al. 2012. Lamotrigine treatment reverses depressive-like behavior and alters BDNF levels in the brains of maternally deprived adult rats. Pharmacol Biochem Behav 101:348-353.
5. Aebi H. 1984. Catalase in vitro. Methods Enzymol 105:121-126.
6. Agarwal S, Draper HH. 1992. Isolation of a malondialdehyde-deoxyguanosine adduct from rat liver DNA. Free Radic Biol Med 13:695-699.
7. Arent CO, Réus GZ, Abelaira HM, Ribeiro KF, Steckert AV, Mina F, Dal-Pizzol F, et al. 2012. Synergist effects of n-acetylcysteine and deferoxamine treatment on behavioral and oxidativeparameters induced by chronic mild stress in rats. Neurochem Int 61:1072-1080.
8. Armagan G, Kanit L, Yalcin A. 2011. D-serine treatment induces oxidative stress in rat brain. Drug Chem Toxicol 34:129-138.
9. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, et al. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
10. Bannister JV, Calabrese L. 1987. Assays for superoxide dismutase. Methods Biochem Anal 32:279-312.
11. Belzung C, Turiault M, Griebel G. 2014. Optogenetics to study the circuits of fear- and depression-like behaviors: A critical analysis. Pharmacol Biochem Behav 122:144-157.
12. Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O. 2001.Antioxidative enzyme activities and lipid peroxidation in major depression: Alterations by antidepressanttreatments. J Affect Disord 64:43-51.
13. Björklund A, Dunnett SB. 2007. Dopamine neuron systems in the brain: An update. Trends Neurosci 30:194-202.
14. Browne CA, Lucki I. 2013. Antidepressant effects of ketamine: Mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161.
15. Butterfield DA, Stadtman ER. 1997. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 2:161-191.
16. Correll GE, Futter GE. 2006. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 7:92-95.
17. da Silva FC1, do Carmo de Oliveira Cito M, da Silva MI, Moura BA, de Aquino Neto MR, Feitosa ML, de Castro Chaves R, Macedo DS, de Vasconcelos SM, de França Fonteles MM, de Sousa FC. 2010. Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res Bull 83:9-15.
18. Davies KJ. 2000. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 50:279-289.
19. Della FP, Abelaira HM, Réus GZ, Antunes AR, Dos Santos MA, Zappelinni G, Steckert AV, et al. 2012. Tianeptine exerts neuroprotective effects in the brain tissue of rats exposed to the chronic stress model. Pharmacol Biochem Behav 103:395-402.
20. Della FP, Abelaira HM, Réus GZ, Santos MA, Tomaz DB, Antunes AR, Scaini G, et al. 2013. Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats. Metab Brain Dis 28:93-105.
21. Detke MJ, Rickels M, Lucki I. 1995. Active behaviors in the rat forced swimming testdifferentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121:66-72.
22. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793-802.
23. Draper HH, Hadley M. 1990. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 86:421-431.
24. Dringen R. 2005. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 7:1223-1233.
25. Finkel T, Holbrook NJ. 2000.Oxidants, oxidative stress and the biology of ageing. Nature 408:239-247.
26. Floyd RA. 1999.Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236-245.
27. Fond G, Loundou A, Rabu C, Macgregor A, Lancon C, Brittner M, Micoulaud-Franchi JA, et al. 2014. Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology 231:3663-3676.
28. Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E. 2009. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24:277-286.
29. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, et al. 2008. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32:140-144.
30. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Stertz L, Kapczinski F, Gavioli EC, et al. 2009. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 33:450-455.
31. Gorwood P. 2008. Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci 10:291-299.
32. Halliwell B, Whiteman M. 2004. Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean? Br J Pharmacol 142:231-255.
33. Hashimoto K, Sawa A, Iyo M. 2007. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310-1316.
34. Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes Dev 18:1926-1945.
35. Hoeffer CA, Klann E. 2010. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci 33:67-75.
36. John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA Jr, Cohen BM, Öngür D, et al. 2012. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology 37:2467-2475.
37. Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, Lyoo IK. 2014. Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol 23:28-35.
38. Kavalali ET, Monteggia LM. 2012. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 169:1150-1156.
39. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
40. Kosten TA, Lee HJ, Kim JJ. 2007. Neonatal handling alters learning in adult male andfemale rats in a task-specific manner. Brain Res 18:144-153.
41. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, et al. 2012. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72:27-28.
42. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. 2014. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4:e469.
43. Levine RL, Garland D, Oliver CN. 1990. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464-478.
44. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (New York, NY) 329:959-964.
45. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
46. Lucca G, Comim CM, Valvassori SS, Réus GZ, Vuolo F, Petronilho F, Dal-Pizzol F, et al. 2009b. Effects of chronic mild stress on the oxidative parameters in the rat brain 54:358-362.
47. Lucca G, Comim CM, Valvassori SS, Réus GZ, Vuolo F, Petronilho F, Gavioli EC, et al. 2009a. Increased oxidative stress in submitochondrial particles into the brain of rats submitted to the chronic mild stress paradigm. J Psychiatr Res 43:864-869.
48. Luft A, Mendes FF. 2005. Low S(+) ketamine doses: A review. Rev Bras Anestesiol 55:460-469.
49. Maes M, Galecki P, Chang YS, Berk M. 2011. A review on the oxidative andnitrosative stress (O&NS) pathways in major depression and their possiblecontribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35:676-692.
50. Mello PB. 2009. Physical exercise can reverse the deficit in fear memory induced bymaternal deprivation. Neurobiol Learn Mem 92:364-369.
51. Moaddel R, Luckenbaugh DA, Xie Y, Villaseñor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, et al. 2014. D-serine plasma concentration is a potential biomarker of (R, S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) 232:399-409.
52. Monteggia LM, Gideons E, Kavalali ET. 2012. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199-1203.
53. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, Hayley AC, et al. 2014. Oxidative & nitrosative stress in depression: Why so much stress? Neurosci Biobehav Rev 45:46-62.
54. Nestler EJ, Carlezon WA Jr. 2006. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159.
55. Ng F, Berk M, Dean O, Bush AI. 2008. Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol 11:851-876.
56. Nowak G, Ordway GA, Paul IA. 1995. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 675:157-164.
57. Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, et al. 2014. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16:119-128.
58. Pandya M, Altinay M, Malone DA Jr, Anand A. 2012. Where in the brain is depression? Curr Psychiatry Rep 14:634-642.
59. Parise EM, Alcantara LF, Warren BL, Wright KN, Hadad R, Sial OK, Kroeck KG, et al. 2013. Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry 74:750-759.
60. Paxinos G, Watson C. 1986. The Rat Brain: Stereotaxic Coordinates. 2nd ed. Australia: Academic Press.
61. Porsolt RD, Le Pichon M, Jalfre M. 1977. Animal model of depression. Nature 266:730-732.
62. Qiu HM, Yang JX, Wu XH, Li N, Liu D, Wang LJ, Qin LJ, et al. 2013. Antidepressive effect of paroxetine ina rat model: Upregulating expression of serotonin and norepinephrine transporter. Neuroreport 24:520-525.
63. Réus GZ, Abelaira HM, dos Santos MA, Carlessi AS, Tomaz DB, Neotti MV, Liranço JL, et al. 2013a. Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behav Brain Res 256:451-456.
64. Réus GZ, Abelaira HM, Maciel AL, Dos Santos MA, Carlessi AS, Steckert AV, Ferreira GK, et al. Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress. Metab Brain Dis, in press.
65. Réus GZ, Abelaira HM, Stringari RB, Fries GR, Kapczinski F, Quevedo J. 2012. Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in theprefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis 27:175-182.
66. Réus GZ, Dos Santos MA, Abelaira HM, Ribeiro KF, Petronilho F, Vuolo F, Colpo GD, et al. 2013b. Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behav Brain Res 242:40-46.
67. Réus GZ, Nacif MP, Abelaira HM, Tomaz DB, dos Santos MAB, Carlessi AS, da Luz JR, et al. 2015b. Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci Lett 584:83-87.
68. Réus GZ, Nacif MP, Abelaira HM, Tomaz DB, dos Santos MAB, Carlessi AS, Matias BI, et al. Ketamine treatment partly reverses alterations in brain derived-neurotrophic factor, oxidative stress and energy metabolism parameters induced by an animal model of depression. Curr Neurovasc Res, in press.
69. Réus GZ, Stringari RB, de Souza B, Petronilho F, Dal-Pizzol F, Hallak JE, Zuardi AW, et al. 2010. Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev 3:325-331.
70. Réus GZ, Stringari RB, Ribeiro KF, Cipriano AL, Panizzutti BS, Stertz L, Lersch C, et al. 2011b. Maternal deprivation induces depressive-like behaviour and alters neurotrophin levels in the rat brain. Neurochem Res 36:460-466.
71. Réus GZ, Stringari RB, Ribeiro KF, Ferraro AK, Vitto MF, Cesconetto P, Souza CT, et al. 2011a. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 221:166-171.
72. Réus GZ, Vieira FG, Abelaira HM, Michels M, Tomaz DB, dos Santos MA, Carlessi AS, et al. 2014a. MAPK signaling correlates with the antidepressant effects of ketamine. J Psychiatr Res 55:15-21.
73. Rojo AI, McBean G, Cindric M, Egea J, López MG, Rada P, Zarkovic N, et al. 2014. Redox control of microglial function: Molecular mechanisms and functional significance. Antioxid Redox Signal 21:1766-801.
74. Rosa PB, Ribeiro CM, Bettio LE, Colla A, Lieberknecht V, Moretti M, Rodrigues AL. 2014. Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice. Pharmacol Biochem Behav S0091-3057:00277-00279.
75. Sattler R, Rothstein JD. 2007. Targeting an old mechanism in a new disease-Protection of glutamatergic dysfunction in depression. Biol Psychiatry 61:137-138.
76. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. 2014. Inflammasomes in neuroinflammation and changes in brain function: A focused review. Front Neurosci 8:315.
77. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. 2013. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 16:1505-1512.
78. Soeiro-de-Souza MG, Salvadore G, Moreno RA, Otaduy MC, Chaim KT, Gattaz WF, Zarate CA, et al. 2013. Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology 38:468-475.
79. Stefanescu C, Ciobica A. 2012. The relevance of oxidative stress status in first episode and recurrent depression. J Affect Disord 143:34-38.
80. Talarowska M, Bobińska K, Zajaczkowska M, Su KP, Maes M, Gałecki P. 2014b. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. Med Sci Monit 20:110-115.
81. Talarowska M, Orzechowska A, Szemraj J, Su KP, Maes M, Gałecki P. 2014a. Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorder. Neuropsychobiology 70:23-28.
82. Taylor MJ, Mannie ZN, Norbury R, Near J, Cowen PJ. 2011. Elevated cortical glutamate in young people at increased familial risk of depression. Int J Neuropsychopharmacol 14:255-259.
83. Teyssier JR, Chauvet-Gelinier JC, Ragot S, Bonin B. 2012. Up-regulation of leucocytes genes implicated in telomere dysfunction and cellular senescence correlates with depression and anxiety severity scores. PLoS One 7:e49677.
84. Turpin FR, Potier B, Dulong JR, Sinet PM, Alliot J, Oliet SH, Dutar P, et al. 2011. Reduced serine racemase expression contributes to age-related deficits in hippocampal cognitive function. Neurobiol Aging 32:1495-1504.
85. Uysal N, Gonenc S, Acikgoz O, Pekçetin C, Kayatekin BM, Sonmez A, Semin I. 2005. Age-dependent effects of maternal deprivation on oxidative stress in infant rat brain. Neurosci Lett 384:98-101.
86. Walker AK, Budac DP, Bisulco S, Lee AW, Smith RA, Beenders B, Kelley KW, et al. 2013. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 38:1609-1616.
87. Willner P. 2005. Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110.
88. Willner P, Scheel-Kruger J, Belzung C. 2013. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev 37:2331-2371.
89. World Health Organization. 2012. Media Centre Fact Sheet No. 369. www.who.int/mediacentre/factsheets/fs369/en/.
90. Wu GJ, Chen TL, Ueng YF, Chen RM. 2008. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 228:105-113.
91. Yang C, Li X, Wang N, Xu S, Yang J, Zhou Z. 2012. Tramadol reinforces antidepressant effects of ketamine with increased levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in rat hippocampus. Front Med 6:411-415.
92. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. 2002. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71:341-344.
93. Zafir A, Ara A, Banu N. 2009. In vivo antioxidant status: A putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 33:220-228.
94. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
95. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, et al. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry 71:939-946.
96. Zhang GF, Wang N, Shi JY, Xu SX, Li XM, Ji MH, Zuo ZY, et al. 2013. Inhibition ofthe L-arginine nitric oxide pathway mediates the antidepressant effects of ketamine in rats in the forced swimming test. Pharmacol Biochem Behav 110:8-12.